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Abstract Introduction
To test the hypothesis that nitric oxide (NO) limits endothe-
lial activation, wetreated cytokine-stimulated human saphe-
nous vein endothelial cells with several NO donors and as-
sessed their effects on the inducible expression of vascular
cell adhesion molecule-i (VCAM-1). In a concentration-
dependent manner, NO inhibited interleukin (IL)-la-stim-
ulated VCAM-1 expression by 35-55% as determined by
cell surface enzyme immunoassays and flow cytometry. This
inhibition was paralleled by reduced monocyte adhesion to
endothelial monolayers in nonstatic assays, was unaffected
by cGMP analogues, and was quantitatively similar after
stimulation by either IL-la, IL-1f, IL-4, tumor necrosis
factor (TNFa), or bacterial lipopolysaccharide. NO also
decreased the endothelial expression of other leukocyte ad-
hesion molecules (E-selectin and to a lesser extent, intercel-
lular adhesion molecule-i) and secretable cytokines (IL-6
and IL-8). Inhibition of endogenous NO production by L-
N-monomethyl-arginine also induced the expression of
VCAM-1, but did not augment cytokine-induced VCAM-1
expression. Nuclear run-on assays, transfection studies us-
ing various VCAM-1 promoter reporter gene constructs,
and electrophoretic mobility shift assays indicated that NO
represses VCAM-1 gene transcription, in part, by inhibiting
NF-cB. We propose that NO's ability to limit endothelial
activation and inhibit monocyte adhesion may contribute to
someofits antiatherogenic and antiinflammatory properties
within the vessel wall. (J. Clin. Invest. 1995. 96:60-68.) Key
words: nitric oxide * endothelium * adhesion molecules
monocytes * atherogenesis
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Nitric oxide (NO)' or closely related molecules account for
the activity of endothelium-derived relaxing factor (1, 2). This
mediator stimulates guanylyl cyclase in smooth muscle cells
leading to vascular relaxation (3). Besides its vasodilatory ef-
fects, NO reportedly has many antiatherogenic properties. NO
reduces platelet aggregability (4), limits vascular smooth mus-
cle cell proliferation (5, 6), inhibits leukocyte adhesion to the
endothelium (7, 8), and prevents monocyte chemotaxis (9).
Chronic provision ofL-arginine in the diets ofhypercholesterol-
emic rabbits has been reported to improve endothelium-depen-
dent vasodilation and to reduce the extent of atherosclerotic
lesions (10). Local leukocyte recruitment to the vessel wall is
an early step in atherogenesis (11), and endothelial-leukocyte
adhesion molecules such as vascular cell adhesion molecule-i
(VCAM-1), intercellular adhesion molecule-I (ICAM-1), and
endothelial-leukocyte adhesion molecule-I (ELAM-1 or E-se-
lectin) may facilitate recruitment of monocytes and lympho-
cytes to sites of lesion formation (12-15). Therefore, factors
which modulate the expression of endothelial-leukocyte adhe-
sion molecules and other endothelial-derived cytokines may be
important in modulating lesion formation. This study sought
to determine whether NO can limit endothelial activation by
inhibiting adhesion molecule expression and monocyte adhe-
sion.
Methods
Reagents. Sodium nitroprusside (SNP) was purchased from Elkins-Sinn
(Cherry Hill, NJ), and 3-morpholino sydnonimine (SIN-1) was a gift
from Dr. A. G. Cassella (Frankfurt, Germany). S-nitroso-glutathione
(GSNO) was chemically synthesized from glutathione and sodium ni-
trite (Sigma Immunochemicals, St. Louis, MO) (16). IL-la was ob-
tained from Hoffmann-La Roche (Nutley, NJ). IL-1,3, TNFa, and IL-
4 were purchased from Genzyme Corp. (Cambridge, MA). Escherichia
coli lipopolysaccharide (LPS) was purchased from Sigma Immuno-
chemicals. Cell-permeable superoxide dismutase (SOD) and catalase
coupled topolyethylene glycol (PEG) were obtainedfrom Sigma/Enzon
(St. Louis, MO) (17). Assays for IL-6 and IL-8 were measured ac-
cording to commercially available enzyme immunoassay (EIA) kits
(R & D Systems, Inc., Minneapolis, MN), assayed directly in human
saphenous vein endothelial cell (HSVEC) supernates.
1. Abbreviations used in thispaper: CAT, chloramphenicol acetyltrans-
ferase; EIA, enzyme immunoassay; GSNO, S-nitroso-glutathione; hpf,
high-power field; HSVEC, human saphenous vein endothelial cells;
ICAM-1, intercellular adhesion molecule-l; L-NAME, L-nitro-arginine
methyl ester; L-NMA, L-N-monomethyl-arginine; NO, nitric oxide;
SIN-1, 3-morpholino sydnonimine; SNP, sodium nitroprusside; VCAM-
1, vascular cell adhesion molecule-1.
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Volume 96, July 1995, 60-68Cell culture. HSVEC were harvested enzymatically with type II
collagenase 0.1% as described (18) and maintained in medium 199
(GIBCO BRL, Gaithersburg, MD), containing Hepes (25 mmol/liter),
heparin (1%), endothelial cell growth factor (50 Ag/m1l), L-glutamine
(1%), antibiotics, and 5% fetal calf serum (Hyclone Laboratories, Lo-
gan, UT). Once grown to confluence, the cells were replated on low
pyrogen fibronectin (1.5 tig/cm2) at 20,000 cells/cm2. HSVEC isolated
by these techniques form a confluent monolayer of polygonal cells and
express von Willebrand factor as determined by their content ofspecific
mRNA and immunoreactive protein (18). Cell number was assessed
after trypsinization in a Neubauer hemocytometer (VWR Scientific
Corp., Philadelphia, PA). Cellular viability was assessed by Trypan
blue exclusion. Bovine aortic endothelial cells (106/100-mm culture
dish, grown in DME with 5% heat-inactivated fetal calf serum) were
used within passage 3 for transfection experiments.
Detection ofcell surface molecules. Assay ofcell surface molecules
was carried out after treatment with cytokines and NO donors for 24 h.
The expression of adhesion molecules was determined by cell surface
EIA or flow cytometry using mouse anti-human monoclonal antibodies
against VCAM-1 (antibody El/6), E-selectin (Ab H18/7), ICAM-1
(Ab HU 5/3), MHC-I (W6/32) (19), or a constitutive and non-cyto-
kine-inducible endothelial cell antigen (El/1) (20). These last two
endothelial surface molecules share a high level of basal constitutive
expression, although MHC-I antigen (Ag), at variance from El/I Ag,
shows some degree of inducibility by cytokines. EIA were carried out
by incubating monolayers first with saturating concentrations ofspecific
monoclonal antibodies against the target molecule, then with biotinyl-
ated goat anti-mouse IgG (Vector Labs, Inc., Burlingame, CA), and
finally with streptavidin-alkaline phosphatase (Zymed Laboratories,
Inc., South San Francisco, CA). Layers were washed three times be-
tween each incubation step, and integrity of the monolayer was moni-
tored by phase-contrast microscopy. The surface expression of each
protein was quantified spectrophotometrically, reading the optical den-
sity ofthe wells (410 nm) 15-60minaftertheadditionofachromogenic
substrate (para-nitrophenylphosphate), as described (19).
Flow cytometric analysis of adhesion molecules was performed by
suspending HSVEC in Hanks' buffered saline solution containing 3
mmol/liter EDTA and incubating the cells with specific primary anti-
body for 30 min at 4°C. After washing, the cells are then exposed to
goat anti-mouse F(ab')2 labeled with fluorescein-isothiocyanate (Cal-
tag Laboratories, San Francisco, CA) at 4°C. After further washing, the
cell suspension was passed through a FACScan6 analyzer (Becton-
Dickinson Immunocytometry Systems, Mountain View, CA). Results
were plotted as intensity offluorescence (arbitrary units, on logarithmic
scale, on the abscissa) versus cell number (on the ordinate, total cells
counted, 104 for each condition).
Assessment oftotal protein synthesis. HSVEC were cultured in 96-
well plates and stimulated with IL-la in the presence and absence of
NO donors. After 24 h, the total cell-associated protein content was
assessedby theamidoblackassay, aspreviously described (21). Briefly,
HSVEC monolayers were fixed with 4% formaldehyde in a 0.1 mol/
liter acetate buffer, pH 3.1, and incubated with amido black B (Sigma
Immunochemicals) to stain cell proteins (22). Unbound dye was rinsed
away with repeated PBS washings, and-dye uptake was determined at
620 nm in an EIA microtiter photometer. In parallel experiments, dye
binding correlated linearly (r = 0.98) with cell number per well, which
in turn was determined by hemocytometric counting oftrypsinized cells
in parallel cultures.
Preparation of human monocytes and U937 cells and adhesion
assays. Humanperipheral blood monocytes wereobtainedbycentrifuga-
tion of white blood cell-enriched blood (Dana Farber Cancer Institute,
Boston, MA) on Ficoll-Hypaque density gradient at 15°C (LMS; Or-
ganon Teknika, Durham, NC) followed by counterflow centrifugation
elutriation in a Beckman J2-21 M/E centrifuge using a JE-6 elutriation
rotor and a 6-ml Sanderson chamber (Beckman Instruments, Inc., Palo
Alto, CA). AmodifiedDoherty's method was used (23, 24): theelutria-
tion buffer was Dulbecco's modified phosphate-buffered saline (GIBCO
BRL), supplemented with 3 mmol/literEDTA and0.25% human serum
albumin (HSA; Sigma Immunochemicals). The mononuclear cell frac-
tion isolated by Ficoll-Hypaque density gradient at the Ficoll-plasma
interface was loaded at 14 ml/min onto the elutriator centrifuge rotor
head (2,500±10 rpm at 10C), and fractions of elutriated cells were
collected. Monocytes wereeluted at21.5 ml/min. Monocytesuspensions
with this technique are 89±4% pure with 8% lymphocyte, < 2% granu-
locyte, and essentially no platelet contamination as determined by light
scatter (FACScan0; Becton Dickinson Immunocytometry Systems) and
cell surface antigen analysis with mAb directed to CD14. Monocytes
were resuspended in cold Dulbecco's modified phosphate-buffered sa-
line containing 0.75 mmol/liter Ca2" and 0.75 mmol/liter Mg2" and
0.2% HSA. U937 cells were obtained through American Tissue Culture
Collection (Rockville, MD) and grown in RPMI 1640 (GIBCO BRL)
containing 10% fetal calf serum. Both monocytes and U937 cells were
concentrated by centrifugation at 1 X 106 cells/ml.
For the adhesion assays, HSVEC were grown to confluency in 6-
well tissue culture plates, after which IL-4 (50 ng/ml) or IL-la (10 ng/
ml) was addedforan additional 24h, inordertoinduce theexpression of
VCAM-1, in the presence or absence ofGSNO (0.2 X IO-3 mol/liter).
For control, some monolayers were treated with a mouse anti-human
monoclonal antibody (El/6) against VCAM-1. The adhesion assay was
performed by adding 1 ml of the concentrated monocytes or U937 cell
suspension to each monolayer under rotating conditions (63 rpm) at
21°C. After 10 min, nonadhering cells were removed by gentle washing
with medium 199, and monolayers were fixed with 1% paraformalde-
hyde. The number of adherent cells was determined by counting six
different high-power fields (hpf) using an ocular grid and a X 20 objec-
tive (0.16 mm2/field). Fields for counting adherent leukocytes were
randomly located at half-radius distance from the center of the mono-
layers.
Northernanalysis. HSVEC RNA was isolatedby ultracentrifugation
through CsCl (25). Total RNA (20 Isg) was separated on a 1.2%
agarose-formaldehyde gel, transferredto anylonmembrane (Hybond-N;
Amersham Corp., Arlington Heights, IL) and immobilizedby shortwave
ultraviolet illumination. cDNA probes were labeled by random priming,
[32P]CTP (3,000 Ci/mmol), and Klenow fragment ofDNA polymerase
I (Pharmacia LKB Biotechnology, Inc., Piscataway, NJ). All blots were
hybridized at42°C overnight and washed (0.2 x SSC, 0.1% SDS, 63°C)
before autoradiography at -80°C for 24-72 h.
Nuclear run-on assay. Nuclei from 3-5 x 107 endothelial cells
were prepared, and in vitro transcription with [a-32P]UTP (800 Ci/
mmol) was performed as described (26). Linearized plasmids (1 4g)
were immobilized onnylon membranes, hybridized toradiolabeled tran-
scripts ( - 5-8 x 107 cpm/ml) at 45°C for 48 h in hybridization buffer
containing 50% formamide, 5 x SSC, 2.5 X Denhardt's Solution, 25
mM sodium phosphate buffer (pH 6.5), 0.1% SDS, and 250 mg/ml
salmon sperm DNA, and washed in 1 x SSC/0.1% SDS at 650C before
autoradiography.
Transfections. The human VCAM-1 promoter constructs containing
the chloramphenicol acetyltransferase (CAT) reporter were described
previouslybyNeishetal. (27). [-755]FO.CATis thefunctionalVCAM-
1 promoter containing AP-1, GATA, and NF-KB binding sites.
[-98]F3.CAT contains the NF-KB binding sites without GATA or AP-
1. [-44]F4.CAT lacks NF-KB bindings sites. Bovine aortic endothelial
cells were transfected with each reporter plasmid (25 jsg) using the
calcium phosphate precipitation method (28). As an internal control
for transfection efficiency, pRSV./3GAL plasmid (10 /ig) was cotrans-
fected in all experiments. Preliminary results using 3-galactosidase
staining indicate that cellular transfection efficiency was - 12-15%.
Cells (60-70% confluent) were stimulated 48 h after transfection with
IL-la (10 ng/ml) and TNFa (10 ng/ml) (alone or in combination with
GSNO [0.2 mmol/liter]), and cellular extracts were prepared 12 h later
using lysis buffer (100 mg/ml leupeptin, 50 pg/ml aprotinin, 0.1 mM
PMSF, 5 mM EDTA, 5 mM EGTA, 100 mM NaCl, 5 mM Tris-HCl, pH
7.4) and one freeze-thaw cycle. The cellular extracts werecentrifuged at
12,000 g for 10 min, and the supernatant was subjected to CAT and /-
galactosidase assay.
CATassays. CAT activity was determined by incubating the super-
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Figure 1. The effect of SNP (black bars), SIN-1 (white bars), and
GSNO (hatched bars) on IL-la (10 ng/ml)-stimulated VCAM-1 ex-
pression. IL-la and NO donors were coincubated for 24 h before cell
surface EIA. Results are expressed relative to absence of NO donors
(percentage ofcontrol). Originalreadings werederivedfromfourdiffer-
ent experiments each consisting of 2 12 different replicates for each
condition. * Significant difference (P < 0.05) compared with controls
and **significant difference (P < 0.01) compared with the effects of
SNP and SIN-1 at 0.4 mol/liter.
natant (100 ul) with [3H]chloramphenicol (50 ,Ci/ml) and n-butyryl
coenzyme A (250 p1g/ml) for 20 h at 37°C (29). The n-butyryl [3H]-
chloramphenicol was then separated from unmodified chloramphenicol
by xylene phase extraction and counted for 2 min in aliquid scintillation
counter (LS1800; Beckman Instruments, Inc.). CAT activity was calcu-
lated from a standard curve using various concentrations of purified
CAT (Promega, Madison, WI). /1-Galactosidase activity was assayed
spectrophotometrically (absorption at 410 nm) and compared with a
standard curve using known amounts ofpurified,/-galactosidase (Sigma
Immunochemicals) as described previously (30). The normalized CAT
activity was calculated as the ratio of CAT to /3-galactosidase activity.
The relative CAT activity was standardized to the normalized FO.CAT
activity having a value of 100. Each experiment was performed three
times in duplicate and all experiments included both positive (highly
expressed pSV40.CAT) and negative (promoterless po.CAT) controls.
Electrophoretic mobility shift assay. Nuclear extracts were prepared
as described (31). The NF-KB oligonucleotide (CCTGGGTTTCCC-
CTTGAAGGGATTTCCCTCC) spanning the two tandem KB sites in
the human VCAM-1 promoter (27) was synthesized by Genosys Bio-
technologies, Inc. (The Woodlands, TX). The oligonucleotide was end-
labeled by T4 polynucleotide kinase (New England Biolabs Inc., Bev-
erly, MA) and [y-32P]ATP (3,000 Ci/mmol) and purified by Sephadex
G-50 columns (Pharmacia LKB Biotechnology, Inc.). Nuclear extract
(10 jig) was added to 32P-labeled NF-KB oligonucleotide (- 20,000
cpm) in a buffer containing 2 pg poly[dI*dC] (Boehringer Mannheim
Corp., Indianapolis, IN), 10 tig BSA, 10 mM Tris-HCl (pH 7.5), 50
mM NaCl, 1 mM DTT, 1 mM EDTA, and 5% glycerol. DNA-protein
complexes were resolved on4% nondenaturing polyacrylamide gel elec-
trophoresed at 12 V/cm in 0.5 x TBE. Specificity was determined
by the addition of p65 or p50 antibodies (15 gg IgG/ml; Santa Cruz
Biotechnology Inc., Santa Cruz, CA) or excess unlabeled (cold) NF-
KB oligonucleotide (20 ng) to the nuclear extracts for 10 min before
addition of radiolabeled probe.
Statistics. Multiple comparisons were performed by one-way analy-
sis ofvariance (ANOVA) and individual differences tested by the Fish-
er's protected least significance difference test after the demonstration
of significant inter-group differences by ANOVA. Student's t test for
Table L Lack ofGSNO Effects on Various Parameters ofHSVEC
Viability and Protein Expression
GSNO
Control (200 jumol/liter, 24 h)
Cell count (cells/103/cm2) 55+6 56±8
Viability (Trypan blue exclusion) > 95% > 95%
Total proteins (OD mU) 60.6±0.8 57.6+2.1
Constitutive endothelial cell
surface Ag (OD mU)
MHC-1 825.5±31.8 823.0±16.7
El/I 1726.5±51.5 1745.0±57.4
Values are mean±SEM.
unpaired data was used to compare the IL-i-stimulated production of
IL-6 and IL-8 with or without GSNO. Comparisons of distribution of
fluorescent intensities at flow-cytometry were performed by the Kolgo-
morov-Smirnov's statistics (32).
Results
Three structurally unrelated NO donors inhibit IL-la-stimu-
lated VCAM-l expression. SNP, SIN-1, and GSNO all inhibited
IL-la-stimulated expression of VCAM-1 in a dose-dependent
fashion, as assessed by cell surface EIA (Fig. 1). Although
maximal inhibition of adhesion molecule expression required
the presence of the NO donors throughout the period of IL-la
stimulation, coincubation of NO donors for periods as short as
1 h could still inhibit VCAM-1 expression, albeit to a lesser
extent (see below).
Incubation of HSVEC with various NO donors for 24 h
resulted in significantly different toxicity profiles, with maxi-
mumsubtoxic concentrations (concentrations producing < 10%
decrease in either cell count or total protein synthesis) being
10-4 mol/liter for SNP and SIN-i and 10' mol/liter for
GSNO. At I0-3 mol/liter, SNP and SIN-I significantly reduced
cell number counts (12 and 14%, respectively), while GSNO
did not. GSNO inhibited total protein synthesis (by 9 and 19%)
only at concentrations of 1 x 10-' and 10 x 10' mol/liter,
respectively. Because of its lower toxicity, most subsequent
experiments used GSNO.
NO itself most likely caused the inhibition of VCAM-1
expression by GSNO, since neither of its chemical precursors,
nitrite and glutathione, produced any inhibitory effects at com-
parable concentrations (data not shown). GSNO (0.2 x 10-'
mol/liter) caused a 35-55% (range) reduction ofIL-la-stimu-
lated VCAM-l expression after 24 h, but had no effect on
the surface expression of two constitutive endothelial surface
proteins, El/1 and MHC-I (Table I).
Flow cytometric analysis also demonstrated inhibition of
VCAM-1 expression by GSNO (Fig. 2). Unstimulated HSVEC
expressed little or no VCAM-1, as the distribution of fluores-
cence intensity compared with cell number in such conditions
(Fig. 2 A) overlapped that obtained with a control preimmune
serum (not shown). Treatment with GSNO did not affect basal
VCAM-1 surface expression (Fig. 2 B). Stimulation ofHSVEC
with IL-la shifted the cell population to the right and widened
its distribution (Fig. 2 C), indicating increased VCAM-1 ex-
pression in the cell population. Compared with IL-la alone,
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Figure 2. Flow cytometric analysis of endothelial cells using antibody
to VCAM-1. (A) Control (no IL-la, no GSNO); (B) the effect of
GSNO (0.2 x 10-3 mol/liter) after 24 h; (C) the effect of IL-la (10
ng/ml) after 24 h; and (D) combination of IL-la and GSNO. Plots
represent the distributions of relative fluorescence intensities (in arbi-
trary units, or "channels," on the abscissas, on a logarithmic scale) as
a function of cell number (on the ordinates). Cell number analyzed in
each condition was 10,000. Insets represent the median values of the
distribution±SEM. Panels shown are from one of two separate experi-
ments using different sets of HSVEC monolayers.
GSNO, when added with 11L-la, shifted the distribution left-
ward, decreasing both its median value and its dispersion (Fig.
2 D). These results indicate that, under GSNO treatment, fewer
cells expressed VCAM-1 and, on the average, each cell did so
to a lesser extent. Controls for flow cytometry included the
use of an antibody against a constitutive and non-cytokine-
inducible endothelial antigen (Ab El/1), with which all distri-
butions appeared uniformly shifted to the right, and a preim-
mune serum (results not shown), which yielded distributions
similar to those shown in Fig. 2, A and B.
GSNO inhibits other cytokine-stimulated cell-associated
and secreted molecules. We investigated the effect of GSNO
on other cytokine-inducible endothelial proteins, including two
other endothelial-leukocyte adhesion molecules, E-selectin and
ICAM-1, and two secretable proteins, IL-6 and 11L-8. GSNO
inhibited cytokine-induced surface expression or secretion of
each of these proteins (Fig. 3 and Table II). In comparative
experiments, inhibition of inducible ICAM-1 expression, how-
ever, was negligible compared with that of either VCAM-1 or
E-selectin (Fig. 3). GSNO did not affect basal (constitutive)
ICAM-1 expression. Inhibition of IL-8 also was lower than for
IL-6 (Table II). These experiments indicate thatNO selectively
decreases production of certain cytokine-induced molecules in
endothelial cells.
GSNO inhibits VCAM-J expression in response to other
cytokines. We assessed and compared the inhibition ofVCAM-
1 expression by GSNO in response to a variety of structurally
unrelated agonists such as IL-1p3, IL-4, TNFa, and LPS. GSNO
inhibited VCAM-1 expression to virtually the same extent with
each stimulus tested (Fig. 4), independent of the relative po-
tency of the stimulus.
Maximum inhibition of VCAM-J by GSNO requires pro-
1500
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Figure 3. Comparative expression of VCAM-1, E-selectin, and ICAM-
1 in HSVEC in the presence or absence of IL-la (10 ng/ml, 24 h),
with or without GSNO (0.2 x 10'- mol/liter), as assessed by cell
surfaceETA. Datarepresent 2 12replicates foreach condition. * Statis-
tically significant differences (P < 0.05) between groupsjoined by the
horizontal lines.
longed incubation. GSNO inhibited IL-la-stimulated VCAM-
1 expression after 1 h. However, the continuous presence of
this NO donor during cytokine stimulation produced greater
inhibition. In experiments in which exposure to the NO donor
was stopped at various time points after the coaddition of the
NO donor and IL-la, GSNO inhibited VCAM-1 expression by
14, 27, and 45% with 1, 6, and 24 h of coincubation, respec-
tively. The effect ofSNP and SIN-I at the same concentrations,
on the other hand, did not increase beyond the level observed
after 1 h (38% inhibition).
GSNO decreases monocyte adhesion. Monocytes adhered
little to unstimulated HSVEC (control) under nonstatic condi-
tions at 21°( (Fig. 5, left). Exposure of HSVEC to IL-la (10
ng/ml, 24 h) increased monocyte adhesion substantially (Fig.
5, middle). Treatment of HSVEC with GSNO (0.2 X 10-3
mol/liter) inhibited IL-la-induced monocyte adhesionby 61%
(Fig. 5, right). 11-4 yielded qualitatively similar results (base-
line: 2±1 cells/hpf; IL-4 50 ng/ml: 27±5 cells/hpf; 11L-4
+ GSNO: 8±3 cells/hpf, corresponding to a 70% inhibition).
Similar effects were also observed for U937 cell adhesion (not
Table II. The Effect ofNO (GSNO, 200 pmolliter, 24 h)
on the Secretion ofIL-6 and IL-8
IL-6 IL-8
Inhibition Inhibition
pg/105 cells by GSNO pg/105 cells by GSNO
Control, no IL-la < 20 25.9±3.0
Control + GSNO < 20 ND 25.8±1.3 < 1%
IL-la (10 ng/ml) 286.0±19.8 970.5±31.0
IL-la + GSNO 142.0±3.3* 50% 723.1±46.7* 25%
Values are mean±SEM ofprotein concentrations assayed in quadrupli-
cate in medium from greater than four HSVEC monolayers in each
control unstimulated condition and greater than eight HSVEC mono-
layers for each stimulated condition. Experimental conditions are similar
to what is described for assay of surface-associated molecules. ND, not
detectable. * P < 0.01 incomparison withcorresponding control condi-
tions.
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shown). These observations parallel the decrease in leukocyte
adhesion molecule expression caused by GSNO.
Inhibition ofVCAM-J expression by GSNO is not mediated
by cGMP. To test whether cGMP mediates the inhibitory effect
of NO donors on VCAM-1 levels, we tested the effects on IL-
la-stimulated VCAM-l expression of two membrane-perme-
able cGMP analogues, dibutyryl cGMP and 8-bromo cGMP, in
arange ofconcentrations from 10-8 to IO-5 mol/liter. We chose
these concentrations because they did not produce toxic effects
on endothelial cells (as judged by morphology, Trypan blue
exclusion, and cell counting) during the 24-h incubation and
because they encompass concentrations able to mimic vasodila-
tory and antiplatelet effects of NO (3). Neither agent reduced
IL-la -stimulated VCAM expression (Fig. 6 A). Furthermore,
there was no trend toward any decline over the entire range of
concentrations explored. Preliminary studies using metabolic
labeling with [y-32P]ATP demonstrated that 8-bromo-cGMP
(1 X 10-3 mol/liter) was effective in activating cGMP-depen-
dent protein kinase activity in endothelial cells, despite lacking
effects on cytokine-induced VCAM-1 expression.
NO decreases VCAM-J mRNA levels. Northern analysis
demonstrated decreased steady state VCAM-1 mRNA levels
upon incubation with either SNP or GSNO at different time
CONTROL IL-la
2 +1 427 ± 62
* control
0 GSNO 200 jwmol/L
Figure 4. The inhibition by GSNO (0.2
X 10-3 mol/liter for 24 h) of VCAM-1 ex-
pression by HSVEC in response to different
stimuli: IL-la (10 ng/ml), IL-1,i (10 ng/
ml), TNFa (10 ng/ml), IL-4 (50 ng/ml),
and LPS (1 pg/ml), all administered for 24
h. n = 16 foreach different condition. * Sta-
tistically significant differences (P < 0.05)
between groups joined by the horizontal
lines.
points after IL-la addition (Fig. 6 A). Densitometric analysis
of autoradiographic bands showed a 56-70% decrease com-
pared with control levels, in good agreement with the fall in
protein expression as quantified by cell surface EIA. Further-
more, GSNO (0.2 X i0' mol/liter) diminished VCAM-1
mRNA expression over a range of IL-la concentrations (0.1-
100 ng/ml) (Fig. 6 B). Inhibition of endogenous NO with L-
N-monomethyl-arginine (L-NMA; 1 X i0' mol/liter) aug-
mented the expression of VCAM-1 mRNA in unstimulated
cells, but had lesser effect on VCAM-1 mRNA expression in
TNFa-stimulated cells (Fig. 6 C). In addition, the induction of
VCAM-1 mRNA expression by TNFa was blunted by cell-
permeable PEG-catalase, and to a lesser extent, PEG-SOD, sug-
gesting involvement of hydrogen peroxide to a greater extent
than superoxide anion in TN'Fa-induced modulation ofVCAM-
1 mRNA (Fig. 6 D).
NO decreases cytokine-stimulated VCAM-1 transcription.
In the presence of actinomycin D, GSNO did not significantly
affect the half-life of VCAM-1 mRNA (5.2±+1.8 h vs. 4.7±1.5
h, P = NS) indicating that the inhibitory effect of NO on
VCAM-1 expression occurs at the level of transcription (Fig.
7 A). Nuclear run-on assays demonstrated a transcriptional ef-
fect of NO on VCAM-1 expression (Fig. 7 B). Transcription
IL-la + GSNO
165±47
Figure 5. The inhibition by GSNO (0.2 x 10-3 mol/liter for 24 h) ofmonocyte adhesion to HSVEC induced by IL-la, coadministered with GSNO
for 24 h. Photographs represent randomly chosen fields at half-radius distance from the center of the well in one of three similar comparative
experiments. Insets represent monocyte cell counts±SEM (n = 6 for each condition) within a high-power field (magnification grid area of 0.16
mm2)
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experiment yielded similar results.
of the 3-tubulin gene served as an internal control, and lack
of hybridization to the insertless vector, pGEM, established
specificity (data not shown).
To localize possible sites of inhibition on the VCAM-1
promoterbyNO, weperformedtransfection studies withvarious
deletional promoter reporter CAT constructs (Fig. 8 A) using
bovine aortic endothelial cells which yielded a higher transfec-
tion efficiency than human endothelial cells. The promoterless
po.CAT and the highly expressed pSV40.CAT served as nega-
tive and positive controls in the reporter assays. The promoter-
less po.CAT and pF4.CAT produced essentially no relative
CAT activity eitherbasally orafterstimulation with TNFa (Fig.
8 B). Stimulation with TNFa of transfectants containing the
fully functional VCAM-1 promoter, FO, increased relative CAT
activity from 101±16 to 1,240±235. Cotreatment with GSNO
resulted in a 76% decrease in relative CAT activity (300±63),
indicating that NO can inhibit TNFa-stimulated VCAM-1 pro-
moter activity.
Transfection studies were also performed using pF3.CAT,
a deletional VCAM-I promoter construct containing two tan-
dem NF-KB sites, but no AP-1 and GATA sites (Fig. 8 B).
Stimulation of pF3.CAT transfectants with IL-la and TNFa
increased relative CAT activity from 73±23 to 474±52, sug-
gesting that binding ofNF-KB may be involved in the induction
of VCAM-1 transcriptional activity, albeit at a significantly
lower level compared with pFO.CAT. Cotreatment with GSNO
reduced the relative CAT activity of pF3.CAT transfectants to
basal levels (139±51).
NO inhibits NF-KB activation. To determine whether NO
inhibits NF-KB activation, electrophoretic mobility shift assays
were performed using radiolabeled oligonucleotide correspond-
ing to the two tandem KB sites in the VCAM-1 promoter (Fig.
9). GSNO (0.2 x 10-3 mol/liter) decreased the amount of
shifted complex induced by TNFa, indicating that NO inhibits
the activation of NF-KB. The shifted complexes were specific
for NF-KB since they were supershifted in the presence ofanti-
bodies to NF-KB subunits and disappeared with excess unla-
beled oligonucleotide. In addition, neither 8-bromo-cGMP (1
X 10-3 mol/liter), glutathione (0.2 x 10-3 mol/liter), nor ni-
trite (0.2 x 10-3 mol/liter) had any effects on activation of
NF-KB (data not shown).
Discussion
We have shown that NO can reduce cytokine-induced expres-
sion ofanumber ofpathophysiologically relevanteffector mole-
cules characteristic of endothelial activation. Upon appropriate
stimulation, the endothelium exhibits increased adhesiveness
for monocytes, lymphocytes, and granulocytes. Increased or
newly induced expression of endothelial-leukocyte adhesion
molecules (e.g., ICAM-1, VCAM-1, and E-selectin) mediates
suchenhancedadhesiveinteractions (13, 14, 33, 34). The secre-
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F3 (.95)
NF- 44B TA) A
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TIME (h)
B _CA_ _ Figure 7. (A) Half-life of
_IL-la (10 ng/ml)-stim-
P-Tubulln - ulated VCAM-1 mRNA
in the presence and ab-
CONTROL TNFd TNFz+ NO sence of GSNO (0.2
X 10-3 mol/liter). Acti-
nomycin D (5 ttg/ml) and GSNO were added 3.5 and 4 h after IL-la
stimulation, respectively. The amount of VCAM-l mRNA (by densi-
tometry) was compared with the amount of VCAM-l mRNA at 4 h
after IL-la stimulation (relative intensity) and plotted as a logarithmic
function oftime (h). Time 0 corresponds to 4 h after IL-la stimulation.
(B) Nuclear run-on assay showing the effects ofNO (GSNO, 0.2 x 10-3
mol/liter) on TNFa-stimulated VCAM-l gene transcription at4 h. Band
intensities were normalized to that of /3-tubulin. There were no bands
observed with linearized pGEM plasmid (data not shown). This is
representative of two separate experiments.
tion of inflammatory cytokines (IL-6) (34) and of leukocyte-
specific chemoattractants, such as IL-8 and MCP-1, also likely
contributes to leukocyte recruitment during inflammatory re-
sponses in vivo (23, 35). NO significantly inhibits the expres-
sion of VCAM-1, E-selectin, and IL-6, and, to a lesser extent,
IL-8 and ICAM-1. Three structurally different NO donors inhib-
ited cytokine-induced VCAM-1 expression and concomitantly
reduced monocyte adhesion to cultured endothelial monolayers.
The lack of effects of nitrite or glutathione renders it unlikely
that our findings were due to mediators other than NO.
The physiologic relevance ofNO's inhibitory effects is sup-
ported by the finding that inhibition of endogenous NO by L-
NMA can also lead to the induction of VCAM-1 expression,
albeit to a lesser degree compared with cytokine activation.
This result suggests that endogenous endothelial NO production
tonically inhibits VCAM-1 expression in endothelial cell cul-
tures. Because induction with cytokines results in much higher
levels ofVCAM-1 expression compared with L-NMA, L-NMA
produced only a small augmentation of VCAM-1 expression in
cytokine-induced endothelial cells. These results agree with our
finding that endogenous levels of NO are not sufficient in lim-
iting cytokine-induced VCAM-1 expression. However, at sites
of inflammation, several cell types such as macrophages and
vascular smooth muscle cells, have the capacity to generate
100-fold higher concentrations ofinducible NO at levels compa-
rable with the amount of NO released by GSNO in our study
(36, 37). Furthermore, higher concentrations of NO could be
l CONTROL
12 TNFax
El TNFhx+GSNO
po.CAT pSV4O CAT pFO.CAT pF3.CAT pF4.CAT
Figure 8. (A) VCAM-1 promoter CAT reporter constructs used in trans-
fection experiments. The length of the promoter upstream from the
initiation start site is denoted in base pairs along with putative nuclear
proteinbinding domains. (B) Transfection studies inbovine aortic endo-
thelial cells using promoterless construct (po.CAT), highly expressed
construct (pSV40.CAT), and various truncated VCAM-1 promoter con-
structs. * Significant difference (P < 0.01) between treatment with
cytokines alone and in combination with GSNO.
encountered by cytokine-activated endothelial cells due to their
close proximity to smooth muscle cells and macrophages at
sites of inflammation and the potential stabilization of NO by
formation of potent adducts (38).
The mechanism by which NO inhibits cytokine-induced ex-
pression of VCAM-1 does not appear to involve stimulation of
guanylyl cyclase since treatment with cGMP analogues does
not reduce VCAM-1 expression. Nor does NO affect the post-
transcriptional half-life of VCAM-1 mRNA, as demonstrated
by the actinomycin D studies. Rather, nuclear run-on assays
and transfection studies demonstrate that NO represses VCAM-
1 gene transcription, in part, by inhibiting nuclear binding pro-
tein NF-KB. However, the finding that [-755]FO.CAT had a
higher CAT activity in response to TNFa compared with
[-98]F3.CAT which contained NF-KB sites, but not AP-1 or
GATA sites, suggests that full transcriptional activity of the
VCAM-1 promoter requires the participation ofnuclear binding
proteins such as c-fos, c-jun, and GATA.
Inhibition of [-98]F3.CAT and NF-KB by NO suggests that
inactivation of NF-KB may be one of the mechanisms underly-
ing NO's inhibitory effects on VCAM-1 expression. Indeed,
other investigators have found that activation of NF-KB plays
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Figure 9. Electrophoretic mobility shift assay showing the effects of
GSNO (0.2 xiO mol/liter) on time-dependent activation of NE-KB
by TNFa (10 ng/ml). Specificity was determined by addition of p65
or p50 antibodies (supershift) or unlabeled (cold) NE-KB oligonucleo-
tide (20 ng) to the nuclear extracts. Three separate experiments yielded
similar results.
a major role in transcriptionally inducing the expression of ad-
hesion molecules and various inflammatory cytokines such as
I1L-6 and IIL-8 (39,40). Since the activation of NF-KB by TNFa
is thought to occur, in part, via reactive oxygen species (41,
42), NO may inhibit NF-KB by scavenging and inactivating
superoxide anion. The reaction of NO and superoxide anion is
one of the fastest reactions known in biological systems and is
almost three times faster than that between superoxide anion
and SOD (43). However, at biological pH, the spontaneous
dismutation of superoxide anion may be sufficiently rapid that
addition of SOD may not appreciably alter the formation of
hydrogen peroxide. Our findings that catalase, and to a lesser
extent, SOD, inhibited cytokine-induced VCAM-1 mRNA ex-
pression agrees with reports that NF-KB is a more hydrogen
peroxide-sensitive rather than superoxide anion-sensitive tran-
scription factor (44).
The ability of NO to inhibit monocyte adhesion to endothe-
lium. is consistent with previous observations (7, 8). Bath and
co-workers (9) reported that NO inhibits monocyte adhesion
to endothelium in vitro, without altering expression of CDlI lb/
CDL18, one of the cognate ligands on monocytes for endothelial-
leukocyte adhesion molecules. In experiments superfusing a cat
mesenteric preparation with inhibitors of NO production (L-
NMA and L-nitro-arginine methyl ester [L-NAME]), Kubes
and collaborators (7) also showed that such inhibitors increase
leukocyte (mostly neutrophil) adhesion to mesenteric venules.
They also showed that increased expression of CDllb/CD18
on theleukocyte surfacecouldnotaccountforL-NAME's effect
(7). Other in vivo studies by Kurose and colleagues (45) have
also documented modulation ofmonocyte adhesion to endothe-
lial cells by L-NAME and reversal by cGMP analogues. This
result contrasts with our finding that cGMP analogues do not
affect cytokine-induced expression ofVCAM-1. Several possi-
bilities could account for this difference. First, these in vivo
studies showed induction of endothelial-leukocyte adhesion by
L-NAME rather than by cytokines. Perhaps induction of
VCAM-1 by L-NAME is amenable to reversal by cGMP ana-
logues. Second, these studies cannot separate cGMP effects
on hemodynamics and/or leukocytes from direct alterations in
endothelial functions. Furthermore, induction ofother adhesion
molecules (i.e., ICAM-1 or E-selectin) by L-NAME treatment
may depend partially on cGMP-dependent pathways. In the
present study, by selectively exposing cultured endothelial cells
to NO, we have identified endothelial cells as a potential target
of NO's effect in limiting leukocyte adhesion to VCAM-1.
As mentioned previously, several lines of evidence, both in
vitro and in vivo, have recently suggested a role forendogenous
NO as an antiatherogenic autacoid (46). Our in vitro study
provides a link between NO production and monocyte adhesion
and offers clues as to the mechanism of such an effect. Local
generation of sufficiently high amounts of NO by either endo-
thelial cells themselves orby otherneighboring cells inresponse
to inflammatory stimuli could provide a homeostatic regulation
ofmonocyte adhesionunderphysiological conditions within the
vessel wall. Endothelial dysfunction resulting in reduced level
of NO activity can lead not only to an imbalance in vascular
tone, favoring acute vasoconstriction (1, 2), butcan also impair
an endogenous negative feedback loop that limits VCAM-1
expression, leukocyte adhesion, and atherogenesis.
In summary, we have shown that exogenous as well as
endogenous sources of NO can limit the degree of endothelial
activation. The ability of NO to inhibit the expression of endo-
thelial-leukocyte adhesion molecules and certain proinflamma-
tory cytokines makes it a potentially important regulator of
inflammatory trafficking within the vessel wall.
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